The recurrence rate of non-small cell lung cancer varies significantly depending on the initial stage at diagnosis and the treatment received, with early-stage localized disease experiencing lower recurrence rates compared to advanced stages. While stage 1 patients treated with surgery often see lower rates of return, locally advanced stages encounter higher recurrence probabilities, and stage 4 metastatic disease carries high rates of systemic progression, though modern targeted therapies and immunotherapies have substantially improved long-term disease control and progression-free survival metrics.